Revuforj
(REH-vyoo-forj)
A drug used to treat adults and children aged 1 year and older with acute leukemia that has a certain change in the KMT2A gene and has come back or has not gotten better with other treatment. It is also being studied in the treatment of other types of cancer. Revuforj binds to a protein called menin and keeps it from binding to another protein called KMT2A. This stops or slows the growth of leukemia cells with changes in the KMT2A gene. Also called revumenib citrate.